https://scholars.lib.ntu.edu.tw/handle/123456789/365731
標題: | Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage III colon cancer in Taiwan | 作者: | MING-CHIN YANG HSU, TZU-CHI CHEN, HONG-HWA YANG, MING-CHIN WANG, HWEI-MING CHUANG, JYE-HANN JAO, SHU-WEN CHEN, LI-TZONG |
關鍵字: | 5-fluorouracil/leucovorin; adjuvant therapy; capecitabine; colon cancer; pharmacoeconomics | 公開日期: | 2011 | 卷: | 14 | 期: | 5 | 起(迄)頁: | 647-651 | 來源出版物: | Value in Health | 摘要: | Objectives: To assess the cost-effectiveness of oral capecitabine compared with intravenous bolus 5-fluorouracil/leucovorin (5-FU/LV) in the adjuvant treatment of stage III colon cancer in Taiwan from payer (Bureau of National Health Insurance [BNHI]) perspectives. Methods: A health state-transition model was developed to estimate the incremental costs and effectiveness of capecitabine versus 5-FU/LV. The time horizons studied were: treatment duration (24 weeks) plus 36 months, 48 months, 60 months, 120 months, and lifetime. Costs were expressed in Taiwanese new dollars (NT$). Clinical outcomes, medical resource use, and utilities were extracted from published sources. Unit costs were estimated from BNHI fee schedules, published sources, and local expert opinion. Outcomes and future costs were discounted at 3%. Cost-effectiveness was expressed as cost per quality-adjusted life-month (QALM). The effects of uncertainty were explored through a one-way sensitivity analysis. Results: For the 24-week time period, drug acquisition costs were higher for capecitabine than 5-FU/LV (NT$114,405 vs. NT$4,904 per patient); however, these were offset by the higher administration costs of 5-FU/LV (NT$2,573 vs. NT$204,201 per patient). Overall direct costs for the 24-week treatment period were less with capecitabine than 5-FU/LV (NT$129,327 vs. NT$233,873 per patient). Cost savings with capecitabine were also evident when longer time horizons were considered. Over a lifetime, the projected survival benefit for capecitabine was 7 QALMs. Conclusions: From the perspectives of the BNHI and society in Taiwan, capecitabine not only saves costs but also improves health outcomes compared with 5-FU/LV in the adjuvant treatment of stage III colon cancer. ? 2011 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). |
URI: | http://www.scopus.com/inward/record.url?eid=2-s2.0-80052487378&partnerID=MN8TOARS http://scholars.lib.ntu.edu.tw/handle/123456789/365731 |
DOI: | 10.1016/j.jval.2011.01.010 | SDG/關鍵字: | capecitabine; fluorouracil; folinic acid; adjuvant therapy; article; cancer chemotherapy; cancer patient; cancer staging; colon cancer; controlled study; cost control; cost effectiveness analysis; drug cost; human; major clinical study; national health insurance; outcome assessment; priority journal; quality adjusted life year; sensitivity analysis; Taiwan; Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Cost Savings; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Fluorouracil; Health Resources; Health Services Research; Humans; Kaplan-Meier Estimate; Leucovorin; Models, Economic; National Health Programs; Neoplasm Staging; Outcome and Process Assessment (Health Care); Quality-Adjusted Life Years; Survival Rate; Taiwan; Time Factors; Treatment Outcome |
顯示於: | 公共衛生學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。